Drug Trial Radar · NCT07359820
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jun 4, 2026
Primary completion
Sep 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Elevar TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate if lirafugratinib is efficacious and safe to treat adult patients with previously treated, unresectable, locally advanced or metastatic solid tumors (excluding cholangiocarcinoma) harboring FGFR2 fusion or rearrangement. Participants will: * Take lirafugratinib regularly as instructed by their study doctor. * Visit the clinic as instructed for checkups and tests. * Keep a diary recording each time a dose of lirafugratinib is taken.
Conditions
- FGFR2 Gene Fusion/Rearrangement
- Other Solid Tumors, Adult
Interventions
LirafugratinibDrug
Lirafugratinib is an oral inhibitor of FGFR2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) assessed by Independent Review Committee per RECIST v1.1.Time frame: Approximately every 8 weeks during treatment and every 12 weeks after the last dose in the absence of progressive disease, approximately 36 months.
Locations
19 sites in 5 countries. Site status is shown where the registry gives one.
Mayo Clinic
Phoenix, Arizona · Not yet recruiting
Mayo Clinic
Jacksonville, Florida · Not yet recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
University of Chicago Medical Center
Chicago, Illinois · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Mayo Clinic
Rochester, Minnesota · Not yet recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
The University of Texas M.D. Anderson Cancer Center
Houston, Texas · Recruiting
Institut Bergonie
Bordeaux, France · Not yet recruiting
Centre Georges François Leclerc
Dijon, France · Not yet recruiting
Centre Leon Berard
Lyon, France · Recruiting
Gustave Roussy Cancer Campus
Paris, France · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
START Barcelona-Hospital HM Nou Delfos
Barcelona, Spain · Recruiting
Hospital Universitario Fundación Jiménez Díaz- START MADRID
Madrid, Spain · Recruiting
Hospital Universitario HM Sanchinarro-START MADRID-CIOCC
Madrid, Spain · Recruiting
Sarah Cannon Research Institute UK
London, United Kingdom · Recruiting
The Christie NHS Foundation
Manchester, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.